UCL researchers develop groundbreaking therapy for a common cause of high blood pressure

A minimally invasive therapy that has the potential to transform treatment of a common cause of high blood pressure, has been developed by researchers at UCL, Queen Mary University of London and Barts Health.

InSilicoTrials, Axoltis to develop drugs for neurological disorders

The partnership aims to develop disease-modifying drugs to treat patients with neurodegenerative and traumatic neurologic impairments. Credit: Elif Bayraktar / Shutterstock.com. InSilicoTrials has entered a

July 28, 2023

Stressful life events and insomnia may increase risk of atrial fibrillation in postmenopausal women

After menopause an estimated 1 in 4 women may develop irregular heart rhythms -; known as atrial fibrillation – in their lifetime, with stressful life

August 30, 2023

FDA Approves New Frontline Regimen for Aggressive ALL

The FDA granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in previously untreated adults, the

March 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.